Hikma Pharmaceutic (HKMPF) Downgraded to “Reduce” at HSBC Holdings plc

HSBC Holdings plc downgraded shares of Hikma Pharmaceutic (OTC:HKMPF) from a hold rating to a reduce rating in a report released on Friday morning, StockTargetPrices.com reports.

Shares of Hikma Pharmaceutic (OTC:HKMPF) remained flat at $26.50 during mid-day trading on Friday. The stock’s 50 day moving average is $25.26 and its 200 day moving average is $24.41. Hikma Pharmaceutic has a 52 week low of $20.43 and a 52 week high of $35.25. The company has a market cap of $5.99 billion and a price-to-earnings ratio of 32.40.

Your IP Address:

Stock Target Prices

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/hikma-pharmaceutic-hkmpf-downgraded-to-reduce-at-hsbc-holdings-plc/1709193.html

Receive News & Ratings for Hikma Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceutic and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *